Biodexa Pharmaceuticals PlcBDRX财报
Nasdaq · 医疗保健 · 药物制剂
Biodexa Pharmaceuticals Plc是一家处于临床阶段的生物制药企业，专注于开发癫痫、罕见神经退行性疾病等中枢神经系统疾病的创新疗法，主要面向欧美市场推进多款在研药物的临床试验，满足未被覆盖的患者治疗需求。
主要股东
| 股东 | 持股比例 | 股数 | 变动 | 截至 |
|---|---|---|---|---|
| MERCER STREET GLOBAL OPPORTUNITY FUND, LLC | 9.99% | 109.4M | — | 2024-01-08 |
| Brio | 9.00% | 167.7K | ▼ -0.83pp | 2024-11-20 |
| Ionic Ventures, LLC | 4.90% | 135.5K | — | 2024-02-14 |
| Armistice Capital, LLC | 0.94% | 25.0K | — | 2024-02-14 |
| Iroquois Capital Management L.L.C. | 0.26% | 43.9K | ▼ -7.04pp | 2024-11-14 |
| Cavalry Fund I LP | 0.00% | 59.6K | ▼ -9.90pp | 2024-11-07 |
| CVI Investments, Inc. | 0.00% | — | — | 2024-02-14 |
| Bigger Capital Fund, LP | — | 34.1M | — | 2024-11-12 |